Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2003

View Archived Issues

Dolastatin 10 derivatives with antitumor activity covered by Roche patent

Novel analgesic ORL1 (N/OFQ) ligands identified at Gruenenthal

Fujisawa presents new PARP inhibitors for use in neurological disorders

Euroceltique claims sodium channel blockers for brain ischemia and other uses

Spanish researchers identify isoxazole compounds with antibacterial and antitumor activity

Scientists at Lilly and Ligand present new RXR modulators

Geron licenses hTERT technology to PanCel

Good safety profile reported for PRO-2000 gel in HIV-infected and uninfected women

Atomoxetine effective and well tolerated in adult ADHD

Evaluation of antiangiogenic effects of BMS-275291 with a novel dermal wound assay

Reslizumab decreases eosinophil counts in patients with eosinophilic gastroenteritis

TNX-901 increases the threshold of allergic sensitivity to peanuts

Islet Neogenesis Therapy phase I study completed

Second phase III trial of MS-325 completed

NeuroSearch to develop NS-2359 for ADHD

Xechem seeks orphan drug status for Hemoxin for sickle cell disease

FDA committee reviews Emend data

Levitra approved in E.U.

Emisphere Technologies reports preliminary data from oral insulin mealtime study

Clinical testing of ISV-403 scheduled to begin in second quarter

Potent CCR3 receptor agonist results in internalization and inactivation of the receptor

Avodart introduced in U.K.

Selective iNOS inhibitor GW-274150 ameliorates renal I/R damage

Potential of CB1 receptor antagonist in obesity confirmed in DIO mouse model

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...